Paolo Tarantino: Time to move beyond the one-size-fits all paradigm for residual disease
Paolo Tarantino, Research fellow at Dana-Farber Cancer Institute and Harvard Medical School, shared a post on X by JAMA Oncology, about recent paper by him as first author, titled “Heterogeneity of Residual Disease After Neoadjuvant Systemic Therapy in Breast Cancer” adding:
Authors: Paolo Tarantino, Gabriel Hortobagyi, Sara M. Tolaney, Elizabeth A. Mittendorf
“Time to move beyond the one-size-fits all paradigm for residual disease.
- RCB-1 is different from RCB-3
- TILs+ is different from TILs-
- ctDNA+ is different from ctDNA-
- gene sign are key to understanding why the tumor did not respond.
The future for RD is increasingly tailored.”
Quoting JAMA Oncology’s post below:
“Wide prognostic and biologic heterogeneity exists within the definition of residual disease after neoadjuvant systemic therapy for breast cancer. This article reviews strategies to dissect such heterogeneity and leverage it to improve patients’ outcomes.”
Dr. Paolo Tarantino, MD, is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan. His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023